Johnson & Johnson Innovation is seeking novel therapeutic approaches to inhibit type 2 inflammation. Approaches which have a systemic effect on type 2 inflammation in relevant diseases (e.g., atopic dermatitis, asthma, eosinophilic esophagitis) are of interest.
Novel oral therapeutic strategies targeting the Th2 signalling pathway are of particular interest (e.g., small molecule inhibitors of STAT6, IL-4R etc.). Approaches targeting other relevant pathways are also of interest if they provide a systemic approach with transformational therapeutic potential...